Takayuki Yoshino
Overview
Explore the profile of Takayuki Yoshino including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
442
Citations
13383
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mishima S, Nakamura Y, Tukachinsky H, Taniguchi H, Kadowaki S, Kato K, et al.
J Liq Biopsy
. 2025 Mar;
1:100003.
PMID: 40027285
Background: The tumor mutational burden (TMB) is a genomic biomarker associated with the benefits from immune checkpoint inhibitors (ICIs) cancer therapy. An elevated blood TMB (bTMB) in circulating tumor DNA...
2.
Shiota M, Matsubara N, Kato T, Eto M, Osawa T, Abe T, et al.
J Liq Biopsy
. 2025 Mar;
7:100282.
PMID: 40027233
Purpose: Genomic characterization of the predisposition of tumors to metastasize to specific sites has been performed in a few studies using mainly tissue-derived genomes. This nationwide prospective observational study investigated...
3.
Bando H, Kumagai S, Kotani D, Mishima S, Irie T, Itahashi K, et al.
Nat Cancer
. 2025 Feb;
PMID: 39972105
Platinum-based definitive chemoradiotherapy (dCRT) is the standard treatment for patients with unresectable locally advanced esophageal squamous cell carcinoma (ESCC) that invades the aorta, vertebral body or trachea; however, complete response...
4.
Sakai S, Nomura R, Nagasawa S, Chi S, Suzuki A, Suzuki Y, et al.
PLoS Comput Biol
. 2025 Feb;
21(2):e1012854.
PMID: 39965034
Single-cell spatial omics analysis requires consideration of biological functions and mechanisms in a microenvironment. However, microenvironment analysis using bioinformatic methods is limited by the need to detect histological morphology and...
5.
Sobrero A, Dasari A, Aquino J, Lonardi S, Garcia-Carbonero R, Elez E, et al.
Eur J Cancer
. 2025 Feb;
218:115268.
PMID: 39952149
Introduction: Maintaining or improving health-related quality of life (HRQoL) is as important as extending survival in metastatic colorectal cancer. We report an HRQoL analysis from FRESCO-2 (NCT04322539). Methods: Patients were...
6.
Kobayashi S, Nakamura Y, Hashimoto T, Bando H, Oki E, Karasaki T, et al.
Int J Clin Oncol
. 2025 Feb;
PMID: 39920551
Although the 5-year relative survival rates for resectable solid tumors have improved over the past few years, the risk of postoperative recurrence necessitates effective monitoring strategies. Recent advancements in molecular...
7.
Andre T, Elez E, Lenz H, Jensen L, Touchefeu Y, Van Cutsem E, et al.
Lancet
. 2025 Jan;
405(10476):383-395.
PMID: 39874977
Background: CheckMate 8HW prespecified dual primary endpoints, assessed in patients with centrally confirmed microsatellite instability-high or mismatch repair-deficient status: progression-free survival with nivolumab plus ipilimumab compared with chemotherapy as first-line...
8.
Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial
Kopetz S, Yoshino T, Van Cutsem E, Eng C, Kim T, Wasan H, et al.
Nat Med
. 2025 Jan;
PMID: 39863775
Encorafenib + cetuximab (EC) is approved for previously treated BRAF V600E-mutant metastatic colorectal cancer (mCRC) based on the BEACON phase 3 study. Historically, first-line treatment of BRAF V600E-mutant mCRC with...
9.
Imai M, Nakamura Y, Shin S, Okamoto W, Kato T, Esaki T, et al.
JCO Precis Oncol
. 2025 Jan;
9():e2400385.
PMID: 39823559
Purpose: Human epidermal growth factor receptor 2 (HER2)-targeted therapies have shown promise in treating -amplified metastatic colorectal cancer (mCRC). Identifying optimal biomarkers for treatment decisions remains challenging. This study explores...
10.
Takamori H, Goto T, Kashima S, Yoshino T, Ogata T, Aizawa R, et al.
Jpn J Clin Oncol
. 2025 Jan;
PMID: 39820449
Background: Non-metastatic castration-resistant prostate cancer (PCa) has become clinically important in PCa management, with treatments aiming to delay metastasis. However, limited data exist on its prevalence and patient characteristics in...